載入中
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
一般交易時段
US$24.46
−US$0.81 · -3.21%
盤中時間採用ET。市場資料可能有所延遲。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日內區間
目前US$24.46
52週區間
目前US$24.46
盤中時間採用ET。市場資料可能有所延遲。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日內區間
目前US$24.46
52週區間
目前US$24.46
| 項目（USD） | 2025會計年度 |
|---|---|
| 營收 | 7421.1萬 USD |
| 銷貨成本 | 3250.6萬 USD |
| 毛利 | 4170.5萬 USD |
| 研究與開發 | 3747.1萬 USD |
| 銷售、一般及管理費用 | 3556.8萬 USD |
| 營業費用 | 7303.9萬 USD |
| 利息收入 | 216萬 USD |
| 利息支出 | 40.1萬 USD |
| 折舊和攤銷 | 386.4萬 USD |
| 營業利益 | −3133.4萬 USD |
| 淨利 | −2981.9萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$33.50
上漲空間 36.96%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG2550.73萬1.24%15.57億 USD0.75%US$49.065-4.36%
Vanguard Morningstar Total Stock Market ETFVTI978.07萬0.00%2.3兆 USD0.03%US$381.77-0.04%
iShares Russell 2000 ETFIWM879.36萬0.01%787.4億 USD0.19%US$278.55-0.14%
Vanguard Extended Market ETFVXF418.59萬0.00%954億 USD0.05%US$234.32-0.29%
Vanguard Russell 2000 ETFVTWO233萬0.01%180億 USD0.06%US$112.51-0.13%
iShares Russell 2000 Growth ETFIWO216.45萬0.02%139.17億 USD0.24%US$354.66-0.59%
Schwab U.S. Small-Cap ETFSCHA163.87萬0.01%218.24億 USD0.03%US$32.755-0.11%
Vanguard Russell 2000 Growth ETFVTWG30.34萬0.02%17億 USD0.06%US$259.07-0.55%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
